While awaiting cardiovascular outcomes data that it believes could spark renewed interest and sales in its obesity drug Belviq, Arena Pharmaceuticals Inc. is looking for a new CEO and offering its entire pipeline out for partnering opportunities, the troubled specialty firm said during a Feb. 29 earnings call.
In the wake of consistently disappointing sales for its obesity drug, once expected to yield blockbuster sales, Arena's board asked...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?